$IFBD and its Influence on China’s SaaS Market

• SMEs account for about 60% of China’s production GDP
• However, they have a relatively low adoption of SaaS and automation tools
• Infobird, through innovation and education, is trying to rectify this issue
• By targeting these SMEs, it will be impacting the entire Chinese SaaS market, positioning it as a global leader

As of 2019, the Chinese software-as-a-service SaaS market was estimated between $3.7 billion and $6 billion in value (https://ibn.fm/NBymg). That was just 6% less than the total value of the global SaaS market. This is great for the country. However, when compared to other nations such as the United States, the United Kingdom, Germany, Japan, South Korea, and India, it could use a little more adoption of SaaS and enjoy the benefits and growth that come with it.

Infobird (NASDAQ: IFDB) seeks to address that, mainly through innovation and a marketing strategy meant to grow its market share and the SaaS industry in China.

Infobird has constantly been pushing the envelope regarding the development and launch of the next generation SaaS in China. By targeting leading industries and specific enterprises within these industries, the company is slowly but surely proving what it can do and its potential for taking over both the Chinese and the global markets (https://ibn.fm/qqhHQ).

Currently, small and medium-sized enterprises (“SMEs”) account for about 60% of China’s production GDP. However, their rate of adoption of automation and SaaS is relatively low. This sector’s potential for adopting SaaS far exceeds most markets worldwide, including but not limited to the United States, India, Japan, Germany, and the United Kingdom. Despite its potential, this market is relatively untapped, and Infobird is pushing to fix the situation, firstly educating these organizations and the entrepreneurs therein on the benefits of SaaS, and innovating to suit their needs and wants.

Infobird is a SaaS provider focusing on artificial intelligence (“AI”)-powered customer engagement solutions for the Chinese market. Its tech infrastructure is founded on cloud computing, machine learning, patented Voice over Internet Protocol (“VoIP”) application technologies, and AI (https://ibn.fm/EylhH).

Since its inception back in October 2001, the company has stayed committed to empowering clients with solutions specifically designed for the issues they face, all while increasing their revenue, reducing costs, enhancing service quality, and overall customer satisfaction. With its focus on SMEs, Infobird is trying to grow China into a leading SaaS market globally. By constantly innovating and tailoring its products and services to the customers, the company is slowly demystifying software and automation in business processes.

With its flagship customer engagement software, Infobird can show customers the value of AI customer engagement, along with AI salesforce management. The product, which over 358 customers currently use in industries including health care, education, consumer products, public services, and finance, is proving valuable and essential to improving customer satisfaction and the overall efficiency of an organization’s operations. As such, Infobird is slowly showing its consumers in the Chinese market the value of leveraging its tools and the benefits that come with it.

As it currently stands, Infobird’s role is far bigger than the company itself. Through its efforts to innovate and push its products in the market, it is aiding in growing SaaS adoption within China. More importantly, it allows China to grow and achieve its potential to become a global leader in the SaaS market.

For more information, visit the company’s website at www.Infobird.com/en/index.html.

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

About ChineseWire

ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.

For more information, please visit https://www.ChineseWire.com

Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer

ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com

ChineseWire is part of the InvestorBrandNetwork.

$IDEX a ‘True Powerhouse in the Commercial EV Sector’

Ideanomics (NASDAQ: IDEX) recently completed the acquisition of 100% of privately held US Hybrid, heralding entry into the burgeoning EV powertrain market that is expected to grow at a 16% CAGR between 2020 and 2027. US Hybrid manufactures and sells electric powertrain components and fuel cell engines for medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty cars. The company welcomes US Hybrid CEO Dr. Abas Goodarzi, Ph.D., PE, and his entire team, with the acquisition expected to bring synergistic benefits to the various companies under the Ideanomics Mobility umbrella. A recent article quoted Dr. Goodarzi as saying: “Ideanomics has emerged as a true powerhouse in the commercial EV sector with a synergistic ecosystem of technologies and solutions that covers the entire value chain of electrification. We look forward to leveraging that strength going forward.”

To view the full article, visit https://ibn.fm/AXvMI

About Ideanomics Inc.

Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales-to financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential growth industries. For more information, visit www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

$HWAL 50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th – 15th, 2021

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th – 15th, 2021

$UUUU OPEC’s Rift Impacts U.S. Energy Markets, Including Alternative

Oil prices are almost 40% higher than they began the year. Should the 5% dip over the past week be cause for concern among energy investors? Perhaps the reasons for the dip, impact on competition, and the U.S. production level ought to attract the most focus.

The volatility comes after an aborted meeting of OPEC+, the outcome of which was expected to result in an agreement to increase output, undoing 2020 cuts implemented as the economic lockdowns caused a worldwide glut of crude oil. Instead, OPEC+, which includes the original OPEC cartel members and their oil-producing allies, failed to reach an agreement.

Background:

In 2020 OPEC+ made the decision to severely slow production by nearly 10 million barrels a day as demand vanished from the impact of lockdown orders in economies both large and small. In 2021, the price of oil had risen as much as 50% to its high point as the world began relaxing COVID-era restrictions. Oil-exporting nations are now looking to orchestrate the way forward out of the pandemic crisis and into a world where world energy needs are expected to turn sharply away from petroleum.

The Agreement that Didn’t Happen

The expected agreement that would have increased world oil production fell apart because of a conflict between Saudi Arabia and the U.A.E. The U.A.E. asked to have its production target increased, this would have expanded its percentage of combined OPEC output. Increasing one country’s overall share has a tendency to create conflict. The cartel has stayed united with minimum open conflict, and they only act with a unanimous vote.  The current outcome of “status quo” where the countries are expected to operate under the existing Covid era limited output will have the effect of keeping oil prices high but perhaps cut into potential revenue for the members involved.

U.S. Oil Prices vs. International

U.S. oil prices jumped and then declined yesterday (July 7) as traders deciphered and adjusted to the new OPEC outlook. Oil price volatility isn’t all that the markets experienced by the uncertain future. Oil spreads, the gap between international crude and U.S. production have narrowed.  Producers globally benefit from higher prices. Downstream related business such as refiners prefer fat spreads between U.S. and non-domestic per barrel prices. The narrowing can be seen as a drag on some U.S. energy stocks.

Benchmark U.S. crude oil prices were up about 1% Wednesday morning (July 7), then turned sharply down about 2.6% by 10:40 a.m. E.S.T. Benchmark global crude prices began up about 0.8% before turning lower, dropping about 2.1%. West Texas Intermediate oil futures, the U.S. benchmark, are at $71.48 a barrel. Brent crude oil futures, the international benchmark, are at $72.95 a barrel.

Supply-demand factors in the U.S. are a driver of the spread compression. U.S. inventory post-Covid is at a massive deficit compared to normal levels. As the U.S. economy is sprinting out of last year’s poor economy, the rest of the world is crawling forward from the problems. Narrower spreads tend to reduce U.S. exports and invite imports. This dampens the potential for U.S. producers.

OPEC controls about one-third of global oil production. A rift between two rival countries could impact what occurs with energy sources that compete with oil and even help speed or slow movement away from petroleum. Competition between Gulf allies is heating up in other areas as well as the countries are working to diversify their revenue to be less reliant on oil as the move to reduce dependence accelerates. Increasing Petrodollars ($ U.S. dollars exchanged for crude) are important.

Take-Away

The rift between Saudi Arabia and the U.A.E. may widen or narrow. The countries are going through a challenging time where revising their economies for diversified income appears critical. The U.A.E. is ahead of the Saudis on this; financing additional economic revitalization projects increases the thirst for maximizing oil sales profit.

What occurs halfway across the world impacts the spread between U.S. crude and all other sources. When the spread narrows, other sources become more attractive than they had been. This can impact not just domestic oil sales but related businesses down the line, and even competing energy sources.

$CLXPF Expands to Europe and Provides Update on Intellectual Property Portfolio

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities with various academic and clinical research organizations, including the transfer of its intellectual property assets to its recently formed wholly-owned Ireland subsidiary.

The Company continues its progression of scaling and building upon its IP portfolio of novel psychedelic compounds, delivery platforms and methods of use in psychiatric indications.

Since inception, the Company has been able to progress the following initiatives all of which are accelerated from its growing portfolio of intellectual property:

• expanded IP portfolio to 12 patent filings;

• filed an international patent application (PCT) that brings the potential to obtain patent coverage in 153 countries;

• grown discovery pipeline of psychedelic molecules to 50+;

• progressed with 4 active drug programs utilizing its Novel Psychedelic Compounds of which 3 mental health indications have been selected: Major Depressive Disorder, Alcohol Use Disorder and Anxiety Disorders (General Anxiety Disorder / Social Anxiety Disorder); and

• completed 51 pre-clinical studies to support progression of novel molecules into clinical studies in early 2022

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company scaling and building upon its IP portfolio, progression in relation to the Company’s four active drug programs, and the potential for the Company to obtain patent coverage in 153 countries. There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005953/en/

Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

Media Contacts :
John Kanakis
Cybin Inc.
John@cybin.com

$BRSF Brings Cutting-Edge Tech to the Neurology Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.”

To view the full article, visit: https://ibn.fm/feZf8

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.